TAT(SZ:002433)2020-10-27 16:00Financial Performance - Operating revenue for the reporting period was ¥885,699,689.28, a decrease of 8.91% year-on-year[8] - Net profit attributable to shareholders was ¥14,095,272.36, down 59.97% compared to the same period last year[8] - The company reported a net profit excluding non-recurring gains and losses of ¥8,708,385.00, down 75.52% year-on-year[8] - Net profit decreased by ¥39,989,630.91, a decline of 44.93%, primarily due to increased operating expenses and a decrease in sales of self-made products and health industry products[20] - Total profit decreased by ¥53,016,655.65, a decline of 44.68%, mainly due to increased operating expenses and decreased sales[20] - Net profit for Q3 2020 was CNY 18.66 million, a decline of 54.43% from CNY 40.98 million in Q3 2019[51] - The total comprehensive income attributable to the parent company was CNY 12,073,204.48, compared to CNY 37,334,351.15 in the previous year[52] - Net profit attributable to the parent company was CNY 39,375,285.47, down from CNY 80,653,810.61 year-on-year[61] Cash Flow - The net cash flow from operating activities was -¥14,716,767.43, a decline of 113.35% year-on-year[8] - Cash flow from operating activities decreased by ¥575,333,443.30, a decline of 161.24%, primarily due to decreased revenue and increased marketing expenses[23] - Net cash flow from operating activities was negative CNY 218,508,476.24, a significant decline from positive CNY 356,824,967.06 in the previous year[68] - Total cash inflow from operating activities decreased to ¥1,306,047,150.87 from ¥2,039,376,751.21, reflecting a decline of approximately 36%[72] - Cash outflow from operating activities also decreased to ¥1,242,570,884.55 from ¥1,784,744,050.04, a reduction of about 30%[72] - The net cash flow from investing activities improved to ¥15,578,814.50 from a negative cash flow of ¥96,512,516.60 in the previous period[73] - Financing activities resulted in a net cash inflow of CNY 190,337,407.72, a recovery from a net outflow of CNY 325,533,917.77 in the previous year[69] Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,957,822,147.12, an increase of 1.74% compared to the end of the previous year[8] - Cash and cash equivalents decreased by ¥84,406,729.78, a drop of 30.86% compared to the end of the previous year[16] - Current liabilities increased by ¥1,200,766,092.31, a rise of 54.64%, mainly due to the increase in short-term borrowings and the transfer of bonds payable due within one year[17] - Total liabilities increased to CNY 3,525,090,541.22 from CNY 3,407,956,278.33, marking a rise of about 3.4%[43] - The company's total assets as of September 30, 2020, were CNY 8.77 billion, a decrease from CNY 9.11 billion at the end of 2019[46] - Total current assets amounted to approximately CNY 5.08 billion, with cash and cash equivalents at CNY 74.39 million and accounts receivable at CNY 222.09 million[79] Investments and Expenses - Investment income increased by ¥24,689,989.05, a growth of 1275.96%, mainly due to the transfer of 1.5% equity in subsidiary Kang Aido[19] - Research and development expenses for the year-to-date were CNY 9,302,290.49, an increase from CNY 8,584,296.12 in the previous year[62] - The company reported an investment loss of CNY -853,959.15, compared to a gain of CNY 2,462,418.82 in the previous year[54] - The company's R&D expenses for Q3 2020 were CNY 4.76 million, a slight increase from CNY 4.53 million in Q3 2019[50] Strategic Plans - The company plans to sell up to 60% of its stake in subsidiary Guangdong Kang Aido Digital Health Technology Co., Ltd. to focus on its main business and improve its financial structure[27] - The company plans to focus on market expansion and new product development to drive future growth[60] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[82]